Fibrosis-4 stage of liver fibrosis linked with CV events in ACS patients regardless of diabetes status
China: Liver fibrosis staged by the Fibrosis-4 (FIB-4) index corresponds to an increased risk of myocardial infarction, MACCE, and mortality in acute coronary syndrome (ACS) patients who underwent PCI independent of diabetes status, a recent study has shown. However, it was not associated with stroke and bleeding events.
The findings, published in Diabetes Research and Clinical Practice, suggest that FIB-4 may be helpful in risk stratification of ACS patients independent of the presence or absence of diabetes.
Jingjing Song and a research team from China and colleagues conducted the study to examine the effect of liver fibrosis, assessed by the Fibrosis-4 index, on cardiovascular events in patients with the acute coronary syndrome with and without type 2 diabetes mellitus (T2DM).
For this purpose, the researchers analyzed 6563 ACS patients undergoing PCI. The participants were divided into three groups based on the literature-based FIB-4 cut-offs: < 1.45, 1.45-3.25, and ≥3.25.
The authors reported the following findings:
- During the median 2.4-year follow-up, 270 major adverse cardiac and cerebrovascular events and 194 major bleeding were recorded.
- Intermediate or high FIB-4 scores were significantly associated with an elevated risk of MACCE, mortality, and myocardial infarction but not related to ischemic stroke and major bleeding.
- Further restricted cubic spline analysis showed that FIB-4 as a continuous variable was positively associated with increased adjusted risk of MACCE.
- The results were consistent in subgroups with and without type 2 diabetes.
Liver fibrosis assessed by the FIB-4 index was shown to be linked with myocardial infarction, mortality, and MACCE but not bleeding events and stroke in acute coronary syndrome patients, regardless of type 2 diabetes status.
"The FIB-4 index is useful to improve risk stratification for ischemic cardiac events in ACS patients," the authors wrote. "The study prompted liver fibrosis screening with non-invasive indices in ACS patients with or without type 2 diabetes to identify high-risk patients and help decision-making in clinical practice."
Reference:
The study titled "Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus" was published in Diabetes Research and Clinical Practice. DOI: https://doi.org/10.1016/j.diabres.2022.110206
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.